Device Trial Radar · NCT02717416
Hemostatic Powder Following Injection Therapy Versus Conventional Dual Therapy for Endoscopic Hemostasis for Non-variceal Upper Gastrointestinal Bleeding
Last checked: Nov 19, 2026Latest source record: Jan 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
226
Actual
Start
Jul 1, 2017
Primary completion
Apr 26, 2021
Study completion May 30, 2021
Sponsor
- Lead sponsor
- Yonsei UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 23, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Acute upper gastrointestinal hemorrhage (UGIH) is a common condition that leads to hospital admission, and has significant associated morbidity and mortality, especially in the elderly. The most common causes of acute UGIH are nonvariceal. Although up 70% of non-variceal bleeds settle with conservative measures, endoscopic therapy is the established method for treating those bleeds for which this is not sufficient. Despite advances and increased expertise in managing upper gastrointestinal bleeding, the associated mortality of up to 15% has remained unchanged for several years. EndoClot is a novel topical hemostatic powder approved for use in non-variceal upper gastrointestinal bleeding. This study examines its efficacy for endoscopic hemostasis in non-variceal upper gastrointestinal bleeding. This is a multicenter, prospective, randomized study.
Conditions
- Upper Gastrointestinal Bleeding
Interventions
Endo-ClotDevice
After epinephine injection therapy, Endo-Clot is applied immediately onto the bleeding lesion. A total of 2 g of AMP® particle powder will be sprayed onto the bleeding lesion by a catheter inserted through a working channel of the endoscope under continuous air flow.
hemoclip or electrical coagulationDevice
After epinephrine injection therapy, hemoclip (HX-610-135, Olympus, Japan) will be applied onto the bleeding lesions. The number of hemoclip will be decided by endoscopist. Electrical coagulation will be applied onto the bleeding lesions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The rate of successful initial hemostasisTime frame: 5 minites after appilication of Endo-Clot
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yonsei university of medical center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.